Safe Prescribing Protect your patients


Extended-Release and Long-Acting
Opioids: Assessing Risks,
Safe Prescribing

Why Should I Participate in This Activity?

ER/LA opioids are approved to treat severe persistent pain. The misuse and abuse of these drugs have resulted in a serious public health crisis of addiction, overdose, and death. On July 9, 2012, FDA approved a risk evaluation and mitigation strategy (REMS) for extended-release (ER) and long-acting (LA) opioid medications.

The goal of this REMS is to reduce serious adverse outcomes resulting from inappropriate prescribing, misuse, and abuse of extended-release or long-acting (ER/LA) opioid analgesics while maintaining patient access to pain medications.

Click here for more information on FDA REMS:

About the Activity

AMA PRA Category 1 Credits™
This activity consists of 6 modules. All modules must be completed in order to receive credit.

Assessing Patients for Treatment with ER/LA Opioid Analgesic Therapy

Scope of the problem
Screening tools
Clinical interview

Initiating Therapy, Modifying Dosing, and Discontinuing Use of ER/LA Opioid Analgesics

Trial strategy
Switching opioids
Exit strategies
Tapering, cautions

Managing Therapy with ER/LA Opioid Analgesics

Setting goals
Written agreements
Monitoring, UDT
Screening for abuse

Counseling Patients and Caregivers about the Safe Use of ER/LA Opioid Analgesics

Drug-drug interactions
Medication reconciliation
Tapering, disposal

General Drug Information for ER/LA Opioid Analgesic Products

Common considerations, instructions
Side effects
Drug interactions

Specific Drug Information for ER/LA Opioid Analgesic Products

Considerations in choosing a drug
Specific drugs, clinical pearls

Additional Resources

Responsible Opioid Prescribing

The FSMB Foundation has released an eBook edition of the newly revised second edition of Responsible Opioid Prescribing: A Clinician's Guide for Kindles, Nooks, iPads and other popular platforms.

Learn More

Sponsored by